Date: 2016-01-05
Type of information: Collaboration agreement
Compound: Nanocyclix®, oncology pharmacology models Predict®, Chi-mice® and Pharmimage®
Company: BMS (USA - NY) Oncodesign (France)
Therapeutic area: Technology - Services - Cancer - Oncology
Type agreement: collaboration
Action mechanism: Nanocyclix® is a medicinal chemistry technology used to obtain macrocyclic small molecules. The technology enhances a ligand\'s potency and selectivity towards its receptor due to conformational pre-organization and tighter binding site recognition. Predict® and Chi-Mice® are oncology pharmacology models. The first one is a translational rodent model and services platform used for the pharmacological qualification of anticancer agents. The Chi-Mice® platform is dedicated to the development of relevant models for the selection of efficient anticancer therapies. Pharmimage® allows the use of pharmaco-imaging in preclinical drug development. Functional and molecular small animal imaging enable a non-invasive quantification of biomarkers to answer questions about target expression, pharmacokinetics and distribution of the candidate, potential toxicities, drug-drug interactions and efficacy.
Disease:
Details: * On January 5, 2016, Oncodesign announced that it has entered into a strategic collaboration agreement with BMS to discover, develop and commercialize novel macrocyclic compounds. The collaboration is based on Oncodesign’s platform of small macrocycles, Nanocyclix®, and will also engage the advanced oncology pharmacology models at Oncodesign for cancer applications, Predict®, Chi-mice® and Pharmimage®. The collaboration will potentially include multiple therapeutic areas and involve phenotypic cell-based approaches.
The goal of the collaboration is to generate novel Nanocyclix® based compounds for targets of interest to BMS. These small macrocycles are highly potent and selective and have favorable characteristics allowing knowledge driven optimization beyond what is typically possible with conventional molecular designs.
Under the terms of the agreement, Oncodesign will be primarily responsible for hit to lead and lead optimization up to the candidate selection stage for oncology targets and potentially for certain non-oncology targets. BMS will be solely responsible for completing preclinical and clinical development of all products arising from the collaboration and for their commercialization globally.
Financial terms: Oncodesign will receive an upfront payment of $3 million and research, development and regulatory based milestone payments of up to $80 million per target. In addition, Oncodesign is eligible to receive tiered royalties and sales based milestones for each product resulting from the collaboration.
Latest news:
